Optilume for urethral strictures
Optilume is a novel drug-coated balloon that is indicated for the treatment of urethral strictures. The technology combines balloon dilation, to expand or widen the strictured area, and the delivery of an anti-proliferative drug (paclitaxel) intended to reduce the rate of stricture recurrence.
|
Status
|
In progress
|
| Process |
MT
|
| ID number |
565
|
Provisional Schedule
| Stakeholder registration opens |
04 October 2021 |
| Scope published |
15 November 2021 |
| Committee meeting: 1 |
18 March 2022 |
| Draft guidance: 1 |
08 April 2022 - 11 May 2022 |
| Committee meeting: 2 |
17 June 2022 |
| Resolution |
18 July 2022 |
| Expected publication |
30 August 2022 |
Project Team
| Project lead |
federica Ciamponi |
Email enquiries
Stakeholders
| Manufacturers |
Urotronic |
| Others |
Association of British Healthcare Industries (ABHI) |
| |
Association of Healthcare Technology Providers for Imaging, Radiotherapy and Care (AXrEM) |
| |
Boston Scientific |
| |
Department of Health and Social Care |
| |
Devices for Dignity |
| |
Greater Manchester Health & Social Care Partnership |
| |
Healthcare Improvement Scotland |
| |
HealthTech Alliance |
| |
Johnson & Johnson Medical Ltd |
| |
Medical Technology Group |
| |
Medicines and Healthcare Products Regulatory Agency |
| |
University of Manchester Wounds Research Group |
| |
NHS England |
| |
The British In Vitro Diagnostics Association (BIVDA) |
| |
NHS Digital |
For further information on how we develop guidance, please see our page about NICE medical technologies guidance